Sulfacetamide sodium salt hydrate

Sulfacetamide is a sulfonamide antibiotic that blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase(DHPS) with IC50 of 9.5 μM. Sulfacetamide is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), which is required for bacterial synthesis of folic acid.

Sulfacetamide sodium salt hydrate化学構造

CAS No. 6209-17-2

サイズ 価格(税別) 在庫状況
JPY 18100 国内在庫あり
JPY 67900 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

製品安全説明書

現在のバッチを見る: S475001 DMSO] 50 mg/mL] false] Water] 50 mg/mL] false] Ethanol] 2 mg/mL] false 純度: 99.77%
99.77

Sulfacetamide sodium salt hydrate関連製品

シグナル伝達経路

Autophagy阻害剤の選択性比較

生物活性

製品説明 Sulfacetamide is a sulfonamide antibiotic that blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase(DHPS) with IC50 of 9.5 μM. Sulfacetamide is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), which is required for bacterial synthesis of folic acid.
Targets
DHPS [1]
9.5 μM
In Vitro
In vitro Sulfacetamide inhibits Arabidopsis DHPS with IC50 of 9.5 μM, pKa=5.4[1]. Sulfacetamide induces anti-proliferative effects on T-47D cells and it is independent of apoptosis and cell cycle arrest. Sulfacetamide treatment lowers expression of p53/DRAM pathway in parallel with upregulation of Akt/mTOR pathway promoting cytoprotective autophagy. The LD50 of sulfacetamide in T-47D cells after 48 h is 41 mM. Sulfacetamide does not cause DNA fragmentation. In cells treated with sulfacetamide, the ATG5 expression level increases suggesting an increase in autophagosome formation in the autophagy pathway. Autophagy induction in the sulfathiazole and sulfacetamide treatments is not accompanied by apoptosis and occurred without any distinctive arrest in a phase of the cell cycle. It triggers autophagy in T-47D cells via a DAPK independent pathway[2]. Sodium sulfacetamide or sulfacetamide is a bacteriostatic agent that is active against sulfonamide-sensitive Gramnegative and Gram-positive bacteria, including Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella spp., Proteus vulgaris, and Nocardia, which are usually isolated in secondary infections of the skin. Sulfacetamide inhibits mannose-6-phosphate isomerase (also known as phosphomannose isomerase (PMI)), which is considered the key enzyme in kinetoplastid energy metabolism[3].
細胞実験 細胞株 human breast cancer T-47D cells
濃度 0.0-50 mM
反応時間 24, 48 and 72 h
実験の流れ Cells are cultured in RPMI medium 1640, supplemented with 10% FBS and 1% penicillin/streptomycin, in a humidified atmosphere of 5% carbon dioxide in air at 37°C. According to MTT assay, the LC50 of sulfathiazole and sulfacetamide after 48 h is determined as 6.5 mM and 41 mM, respectively. Doxorubicin and sodium salt of sulfadrugs are dissolved in culture medium to the final desired concentration based on the determined LC50 and filtered. Cells (at 80% confluency) are incubated with freshly prepared drugs for 48h in a humidified incubator before being trypsinized and washed with phosphate-buffer saline 3 times and stored at −70°C. For cell viability assay, cells are seeded in at least triplicate wells for each concentration of drug per time at 1 × 104 cells/well in a 96-well plate. After 24h of seeding, the cells has grown to ~80% confluency. The medium is changed to that containing drugs at concentrations ranging from 0.0-50 mM. The concentration range for doxorubicin is 0-6 µM. After 24, 48 and 72 h, each well is filled with 25 μl MTT stock solution (4 mg/ml or 100 μg/well) and incubated for 3 h at 37°C. Formazan crystals are dissolved in 100 µl of dimethyl sulfoxide (DMSO) and quantified using a microplate reader at 570 nm. The MTT assays are performed at least 3 times for each drug and the percentage of surviving cells relative to control (untreated sample) is calculated.
In Vivo
In Vivo The LD50 of sulfacetamide for mice is 16,500 mg/kg by the oral route. In humans, the side effects include erythema, moderate swelling, nausea, vomiting, and headache. In addition to these side effects, the occurrence of StevensJohnson syndrome is reported in HIV-positive patients who received sulfacetamide drops for eye infections. All of these side effects, however, are associated with oral administration or high drug absorption through the skin, mucous membranes, and the conjunctiva, whereas topical use is not associated with strong side effects.

化学情報

分子量 254.24 化学式

C8H9N2O3S.H2O.Na

CAS No. 6209-17-2 SDF Download Sulfacetamide sodium salt hydrate SDFをダウンロードする
Smiles CC(=O)[N-]S(=O)(=O)C1=CC=C(C=C1)N.O.[Na+]
保管

In vitro
Batch:

DMSO : 50 mg/mL ( (196.66 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 50 mg/mL

Ethanol : 2 mg/mL

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Sulfacetamide sodium salt hydrateを買う | Sulfacetamide sodium salt hydrate ic50 | Sulfacetamide sodium salt hydrate供給者 | Sulfacetamide sodium salt hydrateを購入する | Sulfacetamide sodium salt hydrate費用 | Sulfacetamide sodium salt hydrate生産者 | オーダーSulfacetamide sodium salt hydrate | Sulfacetamide sodium salt hydrate化学構造 | Sulfacetamide sodium salt hydrate分子量 | Sulfacetamide sodium salt hydrate代理店